Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein-
4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have increased …

Background The predictive power of novel biological markers for treatment response to
immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with …

Introduction Immune checkpoint inhibitors (ICIs) only benefit a subset of cancer patients,
underlining the need for predictive biomarkers for patient selection. Given the limitations of …

Simple Summary Tumor cells can evade destruction via immune cells by expressing
coinhibitory membrane molecules, which can suppress tumor-specific T cells. Immune …

In this exploratory prospective observational study on 40 small cell lung cancer (SCLC)
patients treated with a combination of chemotherapy and immune checkpoint inhibitors …

Ovarian cancer has a poor prognosis due to drug resistance, relapse and metastasis. In
recent years, immunotherapy has been applied in numerous cancers clinically. However …

Focused on the newly secreted tumorous exosomes during melanoma immunotherapy, this
work has pioneered an ultra-sensitive spatiotemporal-specific exosome detection strategy …

Simple Summary In the era of precision medicine and immunotherapy, the isolation and
characterization of exosomes from the peripheral blood mononuclear cells (PBMC-EXs) of …

Simple Summary Tumor cells can evade recognition and killing via immune cells by
expressing co-inhibitory membrane molecules, which suppress the activity of tumor-specific …